摘要
肝细胞癌(hepatocellular carcinoma,HCC)是中国癌症相关死亡第二大常见原因。中国约85%的HCC患者在确诊时已是中晚期,系统治疗(包括化疗、靶向治疗、免疫治疗)联合局部微创治疗(如介入治疗、放射治疗等)是目前主要的治疗方式。钇-90(yttrium-90,^(90)Y)微球选择性内放射治疗(selective internal radiation therapy,SIRT)作为主要局部微创治疗手段在国外已有近20年的临床使用经验,临床研究证明了其治疗肝脏肿瘤的疗效和安全性。相关研究证实了^(90)Y微球SIRT单用在HCC中的局部控制作用,以及其与手术、免疫药物、靶向药物联用的有效性及安全性,同时,^(90)Y微球SIRT对于肝段产生的“放射性切除”效应初步显示出其在HCC根治性治疗方面的应用前景。从HCC姑息治疗、转化治疗、放射性肝段切除等方面综述SIRT在HCC中的应用及研究进展。
Hepatocellular carcinoma(HCC)is the second most common cause of cancer-related deaths in China.About 85%of HCC patients are at intermediate or advanced stage upon diagnosis,of which the common treatment strategy is the combination of systemic therapy(including chemotherapy,targeted therapy and immunotherapy)and local minimally invasive therapy(such as interventional therapy and radiotherapy).As one of the local minimally invasive treatment modalities,selective internal radiation therapy(SIRT)with yttrium-90(^(90)Y)microspheres has been used for nearly 20 years abroad with confirmed efficacy and safety.Benefit in local control of HCC by using SIRT with ^(90)Y microspheres alone or being combined with surgery,immunotherapy and targeted drugs has been demonstrated.Meanwhile,the“radiation resection”effect of SIRT with ^(90)Y microsphere on liver segments sheds light on its promising clinical use as radical treatment for HCC.Herein,the application and recent progress of SIRT with ^(90)Y microspheres in HCC were reviewed in terms of its therapeutic purpose as palliative,transformation or radiation segmentectomy.
作者
牛娜(综述)
林岩松(审校)
NIU Na;LIN Yansong(Department of Nuclear Medicine,Peking Union Medical College Hospital,Chinese Academy of Medical Science and Peking Union Medical College,Beijing 100730,China)
出处
《中国癌症杂志》
CAS
CSCD
北大核心
2021年第5期428-434,共7页
China Oncology
关键词
钇-90微球
选择性内放射治疗
肝细胞癌
Yttrium-90 microspheres
Selective internal radiation therapy
Hepatocellular carcinoma
